Under the	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.						
	ARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN						
APPLICATION DATA SHEET (37 CFR 1.76)							
Title of Invention	USE OF A SERINE PALMITOYL TRANSFERASE (SPT) INHIBITOR TO TREAT ATHEROSCLEROSIS AND DYSLIPIDEMIA						
As the below	As the below named inventor(s), I/we declare that:						
This declaration is directed to:							
	The attached application, or						
	Application No.10/594,348, filed on 09/26/06 (and Preliminary Amendment),						
	as amended on if applicable);						
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;							
	wed and understand the contents of the above-identified application, including the claims, as amended by any ecifically referred to above;						
	WARNING						
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identify theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioner/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.27(a) is made in the application or issuance of a patent. Furthermore, the record from an abandomed application may also be available to the public if the application frequent in the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Decks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.							
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.							
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon;							
Full Name of	Inventor(s)						
Inventor 1	Reynold Homan						
Signature	Pynle Hon Citizen of US						
Inventor 2	Sotirios K. Karathanasis						
Signature	Citizen ofGR						

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 163. The information is used by the public to file (and the PTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vay depending upon the needs of the infortulaciace. Any comments on the amount of time you are required to complete his form should be sent to left information. Officer, U.S. Patent and Trademark Office, Washington, DC 202031. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO, Assibilant Commissioner for Patents, Washington, DC 202031.

PTO/SB/01A (10-05)

Under th	Approve for use through 07517200. Own oed 1902 of U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.						
DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN							
APPLICATION DATA SHEET (37 CFR 1.76)							
Title of Invention	USE OF A SERINE PALMITOYL TRANSFERASE (SPT) INHIBITOR TO TREAT ATHEROSCLEROSIS AND DYSLIPIDEMIA						
As the below	As the below named inventor(s), I/we declare that:						
This declaration is directed to:							
	The attached application, or						
	Application No.10/594,348, filed on 09/26/06 (and Preliminary Amendment),						
	as amended on if applicable);						
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;							
	ewed and understand the contents of the above-identified application, including the claims, as amended by any ecifically referred to above;						
	WARNING						
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identify theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioner/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application or issuance of a patent application (and in the application) or issuance of a patent application (and in the application) application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.							
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for confinuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the confinuation-in-part application.							
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon;							
Full Name of	Inventor(s)						
Inventor 1	Reynold Homan						
Signature	Citizen of						
Inventor 2	Sotirios K. Karathanasis						
Signature	7/1107 Citizen of GR						

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the information Officer, U.S. Pattert and Trademark. Office, Washington, DC 20221. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TOX Assistant Commentsioner for Patterts, Washington, DC 2021.

Under th	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.					
DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN						
APPLICATION DATA SHEET (37 CFR 1.76)						
Title of Invention	USE OF A SERINE PALMITOYL TRANSFERASE (SPT) INHIBITOR TO TREAT ATHEROSCLEROSIS AND DYSLIPIDEMIA					
As the below	named inventor(s), I/we declare that:					
This declaration is directed to:						
	The attached application, or					
	Application No.10/594,348, filed on 09/26/06 (and Preliminary Amendment),					
	as amended on if applicable);					
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;						
	wed and understand the contents of the above-identified application, including the claims, as amended by any ecifically referred to above;					
	WARNING					
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identify theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioner/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is availed that the record of a patent application is explicated in the personal information from the documents before submitting them to the USPTO. Petitioner/applicant an anon-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.						
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filling date of the prior application and the national or PCT International filing date of the continuation-in-part application.						
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereor;						
Full Name of	Inventor(s)					
Inventor 3	Robert L. Panek					
Signature	Dobert 2- Panel Citizen of US					
Inventor 4	Tae-Sik Park					
Signature	Citizen of					

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vay depending upon the needs of the individual case. Any comments on the amount of firm you are required to complete this mem should be sent to left information Officer, U.S. Pattert and Trademark. Office, Washington, DC 2023. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Patterts, Washington, DC 2023.

Title of	ARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPL	CATION USING AN			
	APPLICATION DATA SHEET (37 CFR 1.76)				
Invention	USE OF A SERINE PALMITOYL TRANSFERASE (SPT) INHIBITOR TO TREAT				
As the below	named inventor(s), I/we declare that:				
This declara	ion is directed to:				
	The attached application, or				
	Application No.10/594,348, filed on 09/26/06 (and Preliminary	y Amendment),			
	as amended on if applicable);				
I/we believe to sought;	at I/we am/are the original and first inventor(s) of the subject matter which is clair	ned and for which a patent			
	wed and understand the contents of the above-identifled application, including the ecifically referred to above;  WARNING	ne claims, as amended by a			
	icant is cautioned to avoid submitting personal information in documents filed in				
the USPTO, p them to the U publication of or issuance of application is	support a petition or an application. If this type of personal information is include sittioners/applicants should consider redacting such personal information from IPTO. Petitioner/applicant is advised that the record of a patent application is avi- he application (unless a non-publication request in compliance with 37 CFR 1.21 a patent. Furthermore, the record from an abandoned application may also be an eferenced in a published application or an issued patent (see 37 CFR 1.14). Che brams PTO-2038 submitted for payment purposes are not retained in the application.	e documents before submitt ailable to the public after (3(a) is made in the applicati vailable to the public if the acks and credit card			
material to pa became avail	dge the duty to disclose to the United States Patent and Trademark Office all info entability as defined in 37 CFR 1.56, including for continuation-in-part application ble between the filing date of the prior application and the national or PCT Intem -part application.	s, material information which			
All etatements	made herein of my/own knowledge are true, all statements made herein on infor ther that these statements were made with the knowledge that willful false state sonment, or both, under 18 U.S.C. 1001, and may leopardize the validity of the a				
be true, and fo	somment, or both, under 10 0.3.0. 1001, and may jeopardize and validity of the				
be true, and for by fine or imp					
be true, and for by fine or imp thereon;					
be true, and for by fine or imp thereon; Full Name of	f Inventor(s)	application or any patent iss			
be true, and fi by fine or imp thereon; Full Name of Inventor 3	Finventor(s)  Robert L. Panek	application or any patent iss			
be true, and fi by fine or imp thereon; Full Name of Inventor 3	Finventor(s)  Robert L. Panek  Citizen of	application or any paterit iss			

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the infolvation case. Any comments on the amount of fine you are required to complete this form should be sent to the Chiff information Officer, U.S. Pattert and Trademark Office, Washington, DC 2021. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Pattert, Washington, DC 2021.

X

Approved for use through 07/31/2006. OMB 0861 61-002)

4. Approved for use through 07/31/2006. OMB 0861 60-002

9. Patient and Trademark. Office, U.S. DEPARTMENT OF COMMERCE

Under the Papeanon's Reduction Act of 1995, no persons are required to respond to a collection of information triness fellograps avaid OMB conformation. DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN

APPLICATION DATA SHEET (37 CFR 1.76)					
Title of USE OF A SERINE PALMITOYL TRANSFERASE (SPT) INHIBITOR TO TREAT					
Invention ATHEROSCLEROSIS AND DYSLIPIDEMIA					
As the below named inventor(s), I/we declare that:					
This declaration	This declaration is directed to:				
		The attached application, or			
	$\boxtimes$	Application No.10/59	4,348, filed on 09/26/06 (and Preliminary Amendment),		
*		as amended on	if applicable);		
I/we believe that sought;	it I/we am/a	re the original and first i	inventor(s) of the subject matter which is claimed and for which a patent is		
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;					
	-		WARNING		
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identify theft. Personal information such as social security numbers, bank account numbers, or cried to are numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioner/applicants should consider redacting such personal information from the documents before submitting them to the USPTO, Petitioner/applicant is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be a valiable to the public of the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.					
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.					
All statements made herein of mylown knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon;					
Full Name of Inventor(s)					
Inventor 5 Signature	Mark D	. Rekhter	Citizen of US		
Oignatule	4		CILLEGIUI		
☐ Additional i	inventors are	being named on			

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 163. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any commission the amount of time you are required to complete this form should be sent to effent formation Officer, U.S. Patent and Trademark. Office, Washington, DC 2021. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TOX Assistant Commissioner for Patents, Washington, DC 2021.